A buildup of coronavirus in the lungs is likely behind the steep mortality rates seen in the pandemic, a new study finds. The results contrast with previous suspicions that simultaneous infections, such as bacterial pneumonia or overreaction of the body’s immune defense system, played major roles in heightened risk of death, the investigators say.
Led by researchers at NYU Grossman School of Medicine, the new study shows that people who died of COVID-19 had on average 10 times the amount of virus, or viral load, in their lower airways as did severely ill patients who survived their illness. Meanwhile, the investigators found no evidence implicating a secondary bacterial infection as the cause of the deaths, although they cautioned that this may be due to the frequent course of antibiotics given to critically ill patients.
“Our findings suggest that the body’s failure to cope with the large numbers of virus infecting the lungs is largely responsible for COVID-19 deaths in the pandemic,” says study lead author Imran Sulaiman, MD, PhD, an adjunct professor in the Department of Medicine at NYU Langone Health.
Current guidelines from the Centers for Disease Control and Prevention (CDC), he notes, do not encourage use of antivirals such as remdesivir for severely ill patients on mechanical ventilation. But Dr. Sulaiman says the NYU Langone study results suggest that these medications may still remain a valuable tool in treating these patients.
Despite previous concerns that the virus may prompt the immune system to attack the body’s own lung tissue and lead to dangerous levels of inflammation, the investigators found no evidence that this was a major contributor to COVID-19 deaths in the group studied. In fact, Dr. Sulaiman notes that the strength of the immune response appeared proportionate to the amount of virus in the lungs.
The coronavirus has so far killed more than 4 million people worldwide, researchers say. Those placed on mechanical ventilators in order to breathe fare particularly poorly, with 70 percent nationwide succumbing to the illness. Notably, experts attribute the high mortality seen in other viral pandemics such as the Spanish flu in 1918 and swine flu in 2009 to a secondary bacterial infection. However, it remained unclear whether a similar issue affected people with COVID-19.
The new study, published online August 31 in the journal Nature Microbiology, was designed to clarify the role of secondary infections, viral load, and immune cell populations in COVID-19 mortality, according to Dr. Sulaiman. He says the investigation provides the most detailed survey of the lower airway environment in patients with coronavirus.
For the investigation, the researchers collected bacterial and fungal samples from the lungs of 589 men and women who were hospitalized in NYU Langone facilities in Manhattan and on Long Island. All required mechanical ventilation. For a subset of 142 patients who also received a bronchoscopy procedure to clear their air passages, the investigators analyzed the amount of virus within their lower airways and identified the microbes present by studying small pieces of the germs’ genetic code. The study authors also surveyed the type of immune cells and compounds located in the lower airways.
Among the findings, the study revealed that those who died had on average 50 percent lower production of a type of immune chemical that targets the coronavirus compared with the patients with COVID-19 who survived the illness. These customized proteins are part of the body’s adaptive immune system, a subset of cells and chemicals that “remember” invading newly encountered microbes, leaving the body better prepared for future exposure.
“These results suggest that a problem with the adaptive immune system is preventing it from effectively combating the coronavirus,” says study senior author Leopoldo N. Segal, MD. “If we can identify the source of this issue, we may be able to find an effective treatment that works by bolstering the body’s own defenses,” says Dr. Segal, an associate professor in the Department of Medicine at NYU Langone.
He cautions that the investigators only studied patients with coronavirus who survived their first two weeks of hospitalization. It is possible, he says, that bacterial infections or autoimmune reactions may play a greater role in COVID-19 mortality that occurs earlier.
Dr. Segal says the research team next plans to observe how the microbe community and immune response in the lungs of patients with coronavirus change over time.
Funding for the study was provided by National Institutes of Health grants R37 CA244775, R01 HL125816, R21 AI158997, R01 AI143861, R01 AI143861-02S, R01 DK110014, P20 CA252728, and P30 CA016087; and CDC Foundation grant UWSC1085.1. Further funding was provided by Ingelheim Pharma GmbH & Co., Bristol-Myers Squibb, Celgene Corporation, Genentech Inc., Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis Institutes for Biomedical Research, Pfizer Inc., and Sanofi.
In addition to Dr. Sulaiman and Dr. Segal, other NYU Langone researchers were Luis F. Angel, MD; Jun-Chieh J. Tsay, MD; Benjamin G. Wu, MD; Kelsey Krolikowski, BA; Yonghua Li, MD, PhD; Rosemary Schluger, RN; Stephen Yeung, PhD; Ralf Duerr, MD, PhD; Sara Thannickal; Chang Wang, MS; George Jour, MD; Guomiao Shen, PhD; Joseph Carpenito, BS; Xiuxiu Liu, MD; Kun Ji, MD; Destiny Collazo, BA; Anthony Labarbiera, BA; Nancy E. Amoroso, MD; Shari B. Brosnahan, MD; Vikramjit Mukherjee, MD; David A. Kaufman, MD; Jan Bakker, MD, PhD; Anthony S. Lubinsky, MD; Deepak R. Pradhan, MD; Daniel H. Sterman, MD; Michael D. Weiden, MD; Adriana Heguy; PhD; Ludovic P. Desvignes, PhD; Shohei Koide, PhD; Kenneth A. Stapleford, PhD; Kamal M. Khanna, PhD; Ann Marie Schmidt, MD; Bo Shopsin, MD, PhD; Peter Meyn; Chan Wang, PhD; Akiko Koide, PhD; and Huilin Li, PhD. Other study co-investigators were Matthew Chung, PhD; Stephanie Banakis, MS; and Elodie Ghedin, PhD, at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland.; Lizzette Perez-Perez, MSc; and Emmie De Wit, PhD, at the National Institute of Allergy and Infectious Diseases in Hamilton, Montana; Laura Evans, MD, MSc, at the University of Washington in Seattle; Timothy Uyeki, MD, at the CDC in Atlanta; and Jose Clememte, PhD; Bin Zhang, PhD; and Christian Forst, PhD, at Icahn School of Medicine at Mount Sinai in New York City.